Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Merck KGaA is a global science and technology company operating at the intersection of healthcare, life science, and electronics. Founded in 1668 in Darmstadt, Germany, the company is one of the world’s oldest pharmaceutical and chemical enterprises and operates under the Merck brand in most international markets. In the United States and Canada, its businesses operate as EMD Group due to trademark rights held by Merck & Co., Inc. The company’s American Depositary Receipts trade over-the-counter under the ticker MKKGY.
Merck KGaA’s core activities span prescription medicines, laboratory and bioprocessing solutions, and specialty electronic materials. Its revenue is primarily driven by oncology and neurology pharmaceuticals, consumables and equipment for research and biomanufacturing, and advanced materials used in semiconductor manufacturing and display technologies. The company is majority-owned by the founding Merck family through E. Merck KG, which provides long-term strategic continuity and a governance structure distinct from widely held public peers.
Business Operations
Merck KGaA operates through three primary business segments: Healthcare, Life Science, and Electronics. The Healthcare segment focuses on innovative and specialty pharmaceuticals, with key franchises in oncology, neurology, immunology, and fertility. Major products include cancer therapies such as Erbitux and Bavencio (developed with Pfizer) and neurology treatments such as Mavenclad. This segment generates revenue through global drug sales, partnerships, and regional commercialization agreements.
The Life Science segment, operating largely under the MilliporeSigma brand, supplies tools, reagents, consumables, and services for research, clinical development, and commercial biomanufacturing. The Electronics segment provides specialty chemicals and materials for semiconductor fabrication, displays, and other electronic applications, including lithography materials and OLED components. Operations are supported by a global manufacturing and R&D network, with wholly owned subsidiaries across Europe, North America, and Asia-Pacific, and selective strategic collaborations with pharmaceutical and technology partners.
Strategic Position & Investments
Merck KGaA’s strategy centers on innovation-led growth, portfolio optimization, and targeted capital allocation toward high-growth science-driven markets. The company has emphasized oncology and immunology within Healthcare, biologics and bioprocessing within Life Science, and semiconductor materials within Electronics, aligning with long-term demand trends in healthcare innovation and digitalization.
Significant acquisitions have shaped its portfolio, including Millipore Corporation (Life Science platform), Sigma-Aldrich (expansion of research and bioprocessing capabilities), and Versum Materials (strengthening semiconductor materials in Electronics). The company continues to invest heavily in internal R&D, capacity expansion, and emerging technologies such as gene and cell therapy manufacturing solutions, next-generation chip materials, and advanced biologics, while divesting non-core or lower-growth assets when appropriate.
Geographic Footprint
Merck KGaA is headquartered in Darmstadt, Germany, and maintains a broad global presence across Europe, North America, Asia-Pacific, Latin America, and parts of Africa and the Middle East. The company generates a substantial portion of its revenue outside Germany, with particularly strong market positions in the United States, China, Japan, and major European economies.
Manufacturing, R&D, and commercial operations are distributed globally, supporting both local market access and global supply chains. The Life Science and Electronics businesses have significant operational footprints in the United States and Asia, reflecting proximity to key customers in biopharmaceutical manufacturing and semiconductor production, while Healthcare maintains a balanced presence across developed and selected emerging markets.
Leadership & Governance
Merck KGaA operates under a two-tier governance structure common in Germany, with an Executive Board responsible for management and a Supervisory Board providing oversight. The company’s long-term strategic orientation is influenced by its majority ownership by the Merck family, which emphasizes sustainable growth, scientific excellence, and responsible corporate stewardship.
Key executives include:
- Belén Garijo – Chief Executive Officer
- Helene von Roeder – Chief Financial Officer
- Peter Guenter – Chief Executive Officer, Healthcare
- Udit Batra – Chief Executive Officer, Life Science
- Kai Beckmann – Chief Executive Officer, Electronics
The leadership team articulates a strategy focused on science-driven innovation, disciplined capital allocation, and long-term value creation, supported by strong investment in R&D and a global talent base.